Evidence map›Paper›PMID 34823104›Full record

ArticleCell calcium2022

The Mitochondrial Ca

Murali K Yanda, Vartika Tomar, Robert Cole, William B Guggino, Liudmila Cebotaru

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell calcium, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. The Role of Mitochondria in Polycystic Kidney Disease.International journal of molecular sciences · 2026
    Review
  2. Review
  3. MCU-i4, a mitochondrial CaOncology research · 2025
    Article
  4. Calcium signalling and transport in the kidney.Nature reviews. Nephrology · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Murali K YandaThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Vartika TomarThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Robert ColeThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
William B GugginoThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Liudmila CebotaruThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. Electronic address: lcebotaru@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.R01DK125272 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CEBOTARU, LIUDMILA · 2020 to 2024
$1.9M
NIDDK NIH HHS R01 DK125272
6 · The paper itself

Abstract

Mutations in either of the polycystic kidney disease genes, PKD1 or PKD2, engender the growth of cysts, altering renal function. Cystic growth is supported by major changes in cellular metabolism, some of which involve the mitochondrion, a major storage site for Ca

Indexed as

CystsPolycystic Kidney, Autosomal DominantAnimalsCalciumMiceMitochondriaTRPP Cation ChannelsCalciumTRPP Cation ChannelsAdult onset polycystic kidney diseaseCalciumCFTR modulatorsMitochondria

Identifiers

PMID34823104
PMCPMC8840832
OpenAlexW3215009429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.